Three Months Ended September 30, 2015

Diagnostics

Therapeutics

Corporate

Total

Lymphoseek sales revenue:

United States¹

$

2,942,498

$

—

$

—

$

2,942,498

International

10,024

—

—

10,024

Lymphoseek license revenue

550,000

—

—

550,000

Grant and other revenue

476,755

—

—

476,755

Total revenue

3,979,277

—

—

3,979,277

Cost of goods sold, excluding depreciation and amortization

442,094

—

—

442,094

Research and development expenses,

   excluding depreciation and amortization

3,603,501

297,137

—

3,900,638

Selling, general and administrative expenses,

   excluding depreciation and amortization²

1,063,062

42,487

2,721,844

3,827,393

Depreciation and amortization³

17,013

—

115,216

132,229

Loss from operations⁴

(1,146,393

)

(339,624

)

(2,837,060

)

(4,323,077

)

Other income (expense), excluding

   equity in the loss of R-NAV, LLC⁵

—

—

(3,721,242

)

(3,721,242

)

Equity in the loss of R-NAV, LLC

—

—

(26,785

)

(26,785

)

Net loss

(1,146,393

)

(339,624

)

(6,585,087

)

(8,071,104

)

Total assets, net of depreciation and amortization:

United States

3,750,702

—

13,291,939

17,042,641

International

440,349

—

467

440,816

Capital expenditures

—

—

2,788

2,788

Nine Months Ended September 30, 2015

Diagnostics

Therapeutics

Corporate

Total

Lymphoseek sales revenue:

United States¹

$

6,736,418

$

—

$

—

$

6,736,418

International

15,074

—

—

15,074

Lymphoseek license revenue

883,333

—

—

883,333

Grant and other revenue

1,320,816

—

—

1,320,816

Total revenue

8,955,641

—

—

8,955,641

Cost of goods sold, excluding depreciation and amortization

1,167,141

—

—

1,167,141

Research and development expenses,

   excluding depreciation and amortization

9,610,012

559,888

—

10,169,900

Selling, general and administrative expenses,

   excluding depreciation and amortization²

4,634,279

120,872

8,381,910

13,137,061

Depreciation and amortization³

207,498

—

223,870

431,368

Loss from operations⁴

(6,663,289

)

(680,760

)

(8,605,780

)

(15,949,829

)

Other income (expense), excluding

   equity in the loss of R-NAV, LLC⁵

—

—

(8,808,202

)

(8,808,202

)

Equity in the loss of R-NAV, LLC

—

—

(295,217

)

(295,217

)

Net loss

(6,663,289

)

(680,760

)

(17,709,199

)

(25,053,248

)

Total assets, net of depreciation and amortization:

United States

3,750,702

—

13,291,939

17,042,641

International

440,349

—

467

440,816

Capital expenditures

25,492

—

4,914

30,406

¹

All sales to Cardinal Health are made in the United States; Cardinal distributes the product throughout the U.S. through its network of nuclear pharmacies.

²

General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments.  Marketing and selling expenses are allocated to our individual reportable segments.

³

Depreciation and amortization is reflected in cost of goods sold ($15,496 and $72,237 for the three and nine months ended September 30, 2015), research and development ($1,517 and $10,617 for the three and nine months ended September 30, 2015), and selling, general and administrative expenses ($115,216 and $348,514 for the three and nine months ended September 30, 2015).

⁴

Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.

⁵

Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.